
    
      The study has two components. The first aims to establish a safe dose of ASG-5ME. Once
      identified, the safety and preliminary estimate of antitumor activity of ASG-5ME will be
      tested in additional subjects with castration-resistant prostate cancer (CRPC) who are either
      chemotherapy na√Øve or chemotherapy exposed in expanded cohorts.
    
  